Pharsight

1. Gimoti patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6770262	EVOKE PHARMA INC	Nasal administration of agents for the treatment of gastroparesis	Mar, 2021 (3 years ago)
US11628150	EVOKE PHARMA INC	Nasal formulations of metoclopramide	Dec, 2029 (5 years from now)
US11813231	EVOKE PHARMA INC	Nasal formulations of metoclopramide	Dec, 2029 (5 years from now)
US11020361	EVOKE PHARMA INC	Nasal formulations of metoclopramide	Dec, 2029 (5 years from now)
US8334281	EVOKE PHARMA INC	Nasal formulations of metoclopramide	May, 2030 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 19, 2023

Market Authorisation Date: 19 June, 2020

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED;NASAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
15 mg/spray	30 Dec, 2021	1		16 May, 2030

Strength	Dosage	Availability
EQ 15MG BASE/SPRAY	SPRAY, METERED;NASAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6413549	SALIX PHARMS	Fast-Dispersing solid oral dosage form containing coarse particles	Jul, 2017 (6 years ago)

Market Authorisation Date: 04 September, 2009

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg and 10 mg	24 Aug, 2010	1	15 Aug, 2014	11 Jul, 2017	Extinguished Deferred

Strength	Dosage	Availability
EQ 10MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6221392	MEDA PHARMS	Rapidly dissolving robust dosage form	Apr, 2018 (6 years ago)
US6024981	MEDA PHARMS	Rapidly dissolving robust dosage form	Apr, 2018 (6 years ago)

Market Authorisation Date: 10 June, 2005

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
EQ 10MG BASE	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
EQ 5MG BASE	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued